Lifeboat Foundation

In mental health research, clinical studies deserve more funding.

Researchers have made the breakthrough of couch potatoes’ dreams with a new drug that mimics some of the most important effects of exercise. Scientists from Deakin University in Melbourne published their findings in Cell Reports earlier this week, showing that overweight mice who were given the drug no longer showed signs of cardiovascular disease.

The first of 50 patients to complete a trial for a new HIV treatment in the UK is showing no signs of the virus in his blood.

The initial signs are very promising, but it’s too soon to say it’s a cure just yet: the HIV may return, doctors warn, and the presence of anti-HIV drugs in the man’s body mean it’s difficult to tell whether traces of the virus are actually gone for good.

That said, the team behind the trial – run by five British universities and the UK’s National Health Service – says we could be on the brink of defeating HIV (human immunodeficiency virus) for real.

Continue reading “A new treatment appears to have erased HIV from a patient’s blood” »

There are two kinds of people in Washington, DC, says entrepreneur Dean Kamen. There are the policy experts, whom he calls cynics. And there are the scientists, whom he deems optimists.

Kamen, speaking at the White House Frontiers Conference at the University of Pittsburgh, places himself in the latter camp. Unlike policy wonks and politicians who see diseases like Alzheimer’s or ALS as unstoppable scourges, Kamen points out that previously terrifying diseases were all toppled by medical innovation. The plague, polio, smallpox — all were civilization-threatening epidemics until experimental scientists discovered new ways to combat them.

If that sounds like the kind of disruption that the tech industry has unleashed across the rest of the world, that’s no accident. Kamen, the founder of DEKA, a medical R&D company, says that the same trends that have empowered our computers and phones and communication networks will soon power a revolution in health care. He says that medical innovation follows a predictable cycle. First we feel powerless before a disease. Then we seek ways of treating it. Then we attempt to cure it.

Continue reading “Engineering a Better Body and the End of Disease” »

In the first controlled clinical trial of nicotinamide riboside (NR), a newly discovered form of Vitamin B3, researchers have shown that the compound is safe for humans and increases levels of a cell metabolite called NAD+ that is critical for cellular energy production and protection against stress and DNA damage.

Levels of NAD+ (first discovered by biochemists in 1906) diminish with age, and it has been suggested that loss of this metabolite may play a role in age-related health decline.

Continue reading “First human clinical trial for nicotinamide riboside” »

Follow along with the Exponential Medicine 2016 livestream, presented by Guidewell. Join Singularity University as we explore the convergence of health and technology to catalyze the future of medicine.

Join us on Twitter @ExponentialMed and with #xmed.

Continue reading “Singularity University Live Stream of Exponential Medicine 2016” »

Xconomy National —

Drugs that use molecular scissors to snip out or replace defective genes. Altered mosquitoes meant to sabotage entire disease-carrying populations. Both are potential uses of genome editing, which thanks to the CRISPR-Cas9 system has spread throughout the world’s biology labs and is now on the doorstep of the outside world. But with its first applications could also come unintended consequences for human health and the environment. The U.S. Defense Advanced Research Projects Agency—a famed military R&D group—wants to finance safety measures for the new gene-editing age.

The idea for the funding program, called Safe Genes, is to get out ahead of problems that could bring the field to a screeching halt. “We should couple innovation with biosecurity,” DARPA program manager Renee Wegrzyn, said Tuesday at the SynBioBeta conference in South San Francisco. “We need new safety measures that don’t slow us down. You have brakes in your car so that you can go fast but can stop when you need to.”

Continue reading “With New Program, DARPA To Encourage Safety ‘Brakes’ For Gene Editing” »

Classifying aging as a disease, the debate is hotting up as ICD11 at WHO draws near.

What is considered to be normal and what is considered to be diseased is strongly influenced by historical context (Moody, 2001/2002). Matters once considered to be diseases are no longer classified as such. For example, when black slaves ran away from plantations they were labeled to suffer from drapetomania and medical treatment was used to try to “cure” them (Reznek, 1987). Similarly, masturbation was seen as a disease and treated with treatments such as cutting away the clitoris or cauterizing it (Reznek, 1987). Finally, homosexuality was considered a disease as recently as 1974 (Reznek, 1987). In addition to the social and cultural influence on disease definition, new scientific and medical discoveries lead to the revision of what is a disease and what is not (Butler, 2008). For example, fever was once seen as a disease in its own right but the realization that different underlying causes would lead to the appearance of fever changed its status from disease to symptom (Reznek, 1987). Conversely, several currently recognized diseases, such as osteoporosis, isolated systolic hypertension, and senile Alzheimer’s disease, were in the past ascribed to normal aging (Izaks and Westendorp, 2003; Gems, 2011). Osteoporosis was only officially recognized as a disease in 1994 by the World Health Organization (WHO, 1994).

Go to:

Continue reading “It is time to classify biological aging as a disease” »

How society can profit from treating age-related diseases.

We’re now living longer than ever – only to suffer from diseases of old age. New therapies promise a new lease of life for the elderly – and big profits for investors, says Matthew Partridge.

Over the past century, average life expectancy in most countries has grown substantially. Vastly lower infant mortality, improved living standards, better public sanitation, and the discovery of cures or vaccines for many once-deadly diseases, have seen average life expectancy in most developed nations rise to around 80, compared with 50 in 1900. Developing nations have benefited too. Life expectancy in China, for example, was just 43 in 1960 – it’s 75 today. Indeed, according to the World Health Organisation, no individual nation outside Africa now has a life expectancy of below 60, and even Africa has seen huge gains since 2000, helped by improved anti-malarial measures and wider availability of HIV/Aids treatments.

Continue reading “How we can profit from winning the battle against ageing” »